Classification of Parkinson disease using binary Rao optimization algorithms

2021 ◽  
Author(s):  
Suvita Rani Sharma ◽  
Birmohan Singh ◽  
Manpreet Kaur
Neurology ◽  
2018 ◽  
Vol 91 (14) ◽  
pp. e1275-e1284 ◽  
Author(s):  
Scott A. Sperling ◽  
Binit B. Shah ◽  
Matthew J. Barrett ◽  
Aaron E. Bond ◽  
Diane S. Huss ◽  
...  

ObjectiveTo examine nonmotor outcomes and correlates of quality of life (QoL) 3 and 12 months after unilateral focused ultrasound thalamotomy in tremor-dominant Parkinson disease (TDPD).MethodsTwenty-seven patients with TDPD in a double-blind, sham-controlled, randomized clinical trial underwent comprehensive neuropsychological evaluations. These included assessment of mood, behavior, and QoL at baseline, 3 months, 3 months post crossover in the sham group, and 12 months after active treatment. We used Mann-Whitney U tests to assess differences between the active (n = 20) and sham (n = 7) groups at 3 months and Friedman tests to assess within-group changes after active treatment. We assessed correlations between disease variables and postoperative QoL using Kendall tau-b tests.ResultsThere were no differences in cognition, mood, or behavior between the active and sham groups at 3-month blinded assessment. After active treatment, there were no differences in mood or behavior. Only declines in Stroop Color Naming and phonemic fluency were observed. Patients experienced postoperative improvements in QoL and activities of daily living (ADL). Mood and behavioral symptoms, aspects of cognitive functioning, ADL, and overall motor symptom severity, but not tremor severity specifically, were associated with QoL.ConclusionsIn TDPD, unilateral focused ultrasound thalamotomy appears safe from a cognitive, mood, and behavioral perspective. QoL and ADL significantly improved following surgery. Nonmotor symptoms and ADL were more closely associated with QoL than tremor severity.Classification of evidenceThis study provides Class II evidence that for patients with TDPD, unilateral focused ultrasound thalamotomy did not adversely change cognition, mood, or behavior at 3 months.


Neurology ◽  
2018 ◽  
Vol 90 (21) ◽  
pp. e1849-e1857 ◽  
Author(s):  
Joaquim J. Ferreira ◽  
Andrew J. Lees ◽  
Werner Poewe ◽  
Olivier Rascol ◽  
José-Francisco Rocha ◽  
...  

ObjectiveTo evaluate the effectiveness of opicapone as add-on to levodopa and the effects of switching from entacapone over 1 year of treatment in patients with fluctuating Parkinson disease.MethodsAfter completion of a placebo- and entacapone-controlled double-blind study of opicapone (5, 25, or 50 mg), 495 patients continued to a 1-year extension phase in which patients were treated with opicapone. Patients began with once-daily opicapone 25 mg for 1 week, followed by individually tailored levodopa and/or opicapone dose adjustments. The primary efficacy variable was the change from baseline in absolute “off” time based on patient diaries. Other outcomes included proportion of responders, scale-based assessments, and standard safety assessments.ResultsOne year of treatment with opicapone reduced “off” time by a half-hour (33.8 minutes) vs the open-label baseline and >2 hours (126.9 minutes) vs the double-blind baseline. Whereas patients who were originally treated with opicapone 50 mg in the double-blind phase maintained their efficacy, switching treatments led to further decreases in “off” time (−64.9, −39.3, −27.5, and −23.0 minutes for switching from placebo, entacapone, and opicapone 5 and 25 mg, respectively). Dyskinesia was the most frequently reported adverse event (14.5%) and was managed by adjustment of dopaminergic therapy. No new safety concerns were observed with long-term opicapone administration.ConclusionLong-term use of opicapone provided sustained efficacy over 1 year. Switching from entacapone to opicapone led to enhanced efficacy under the conditions of the study.Classification of evidenceThis study provides Class III evidence that for patients with Parkinson disease and end-of-dose motor fluctuations, long-term use (52 weeks) of opicapone is well tolerated and reduces “off” time.


2017 ◽  
Vol 7 (4) ◽  
pp. 283-295 ◽  
Author(s):  
Ryan E. Korn ◽  
Aparna Wagle Shukla ◽  
Maya Katz ◽  
H. Tait Keenan ◽  
Steven Goldenthal ◽  
...  

AbstractBackground:Previous small-scale studies have demonstrated the feasibility of providing remote specialty care via virtual visits. We assessed the feasibility and benefits of a one-time consultation between a remote Parkinson Disease (PD) specialist and an individual with PD at home on a larger scale.Methods:We conducted a multicenter noncontrolled cohort of virtual visits administered over videoconferencing between remote PD specialists and individuals with PD in their home. Specialists performed a patient history and a PD-specific physical examination and provided recommendations to patients and their local physicians. The primary outcome measures were feasibility, as measured by the proportion of visits completed as scheduled, and the 6-month change in quality of life, as measured by the Parkinson's Disease Questionnaire 39. Additional outcomes included satisfaction with visits and interest in future virtual visits.Results:A total of 277 participants from 5 states enrolled, 258 participants completed virtual visits with 14 different physicians, and 91% of visits were completed as scheduled. No improvement in quality of life was observed at 6 months (0.4-point improvement; 95% confidence interval −1.5 to 0.6; p = 0.39). Overall satisfaction with virtual visits was high among physicians (94% satisfied or very satisfied) and patients (94% satisfied or very satisfied), and 74% of participants were interested in receiving future care via virtual visits.Conclusions:Providing specialty care remotely into the homes of individuals with PD is feasible, but a one-time visit did not improve quality of life. Satisfaction with the visits was high among physicians and patients, who were interested in receiving such care in the future.Classification of evidence:This study provides Class IV evidence that for patients with PD, remote specialty care is feasible but does not improve quality of life.Clinicaltrials.gov identifier:NCT02144220.


Neurology ◽  
2021 ◽  
Vol 97 (14) ◽  
pp. e1404-e1412 ◽  
Author(s):  
Anouk Tosserams ◽  
Lisanne Wit ◽  
Ingrid H.W.M. Sturkenboom ◽  
Maarten J. Nijkrake ◽  
Bastiaan R. Bloem ◽  
...  

Background and ObjectivesGait impairments are common and disabling in Parkinson disease (PD). Applying compensation strategies helps to overcome these gait deficits. Clinical observations suggest that the efficacy of different compensation strategies varies depending on both individual patient characteristics and the context in which the strategies are applied. This has never been investigated systematically, hampering the ability of clinicians to provide a more personalized approach to gait rehabilitation. We had 3 aims: (1) to evaluate patients' awareness and actual use of compensation categories for gait impairments in PD, (2) to investigate the patient-rated efficacy of the various compensation strategies and whether this efficacy depends on the context in which the strategies are applied, and (3) to explore differences in the efficacy between subgroups based on sex, age, disease duration, freezing status, and ability to perform a dual task.MethodsA survey was conducted among 4,324 adults with PD and self-reported disabling gait impairments.ResultsThe main findings are as follows: (1) compensation strategies for gait impairments are commonly used by persons with PD, but their awareness of the full spectrum of available strategies is limited; (2) the patient-rated efficacy of compensation strategies is high but varies depending on the context in which they are applied; and (3) compensation strategies are useful for all types of patients with PD, but the efficacy of the different strategies varies per person.DiscussionThe choice of compensation strategies for gait impairment in PD should be tailored to the individual patient and to the context in which the strategy needs to be applied.Classification of EvidenceThis data provides Class IV evidence that compensation strategies are an effective treatment for gait impairment in patients with PD.


2018 ◽  
Vol 7 (1) ◽  
pp. 27-32
Author(s):  
P. Sindhuja ◽  
P. Ramamoorthy ◽  
M. Suresh Kumar

This paper presents a brief survey on various optimization algorithms. To be more precise, the paper elaborates on clever Algorithms – a class of Nature inspired Algorithms. The Nature Inspired Computing (NIC) is an emerging area of research that focuses on Physics and Biology Based approach to the Algorithms for optimization. The Algorithms briefed in this paper have understood, explained, adapted and replicated the phenomena of Nature to replicate them in the artificial systems. This Cross – fertilisation of Nature Inspired Computing (NIC) and Computational Intelligence (CI) will definitely provide optimal solutions to existing problems and also open up new arenas in Research and Development. This paper briefs the classification of clever algorithms and the key strategies employed for optimization.


Sign in / Sign up

Export Citation Format

Share Document